EMN 2021 | IKEMA: isatuximab addition to Kd improves depth of response in myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses interim analysis results from the Phase III IKEMA trial (NCT03275285) comparing isatuximab, carfilzomib and dexamethasone (Isa-Kd) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory myeloma. The interim analysis found that the overall response rate was high in both arms, however, the addition of isatuximab to Kd improved the depth of response, with 39.7% of patients receiving Isa-Kd achieving a complete response (CR), compared to 27.6% of patients receiving Kd alone. The analysis also found that the measurable residual disease (MRD) was significantly higher in the Isa-Kd arm, and longer progression-free survival (PFS) was observed in patients who achieved MRD-negativity. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Thomas Martin, MD, receives research funding to his institution from Sanofi, AMGEN, Janssen
